Core Insights - Talphera, Inc. announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026, highlighting its focus on innovative therapies for medically supervised settings [1] Group 1: Abstract Presentations - The first poster presentation will discuss a randomized, placebo-controlled, multi-center study evaluating the safety and efficacy of Niyad in patients undergoing Continuous Renal Replacement Therapy (CRRT) who cannot tolerate heparin or are at higher risk of bleeding [2] - The second poster presentation will assess the pharmacokinetics of nafamostat in a porcine model of AKI receiving CRRT, indicating that over 95% of nafamostat was removed by the hemofilter when administered pre-filter [3] Group 2: NEPHRO CRRT Study - The NEPHRO CRRT Study is a prospective, double-blinded trial designed to enroll 70 adult patients in U.S. hospital intensive care units, focusing on those who cannot tolerate heparin or are at risk for bleeding [5] - The primary endpoint of the study is the mean post-filter activated clotting time using Niyad versus placebo over the first 24 hours, with key secondary endpoints including filter lifespan and dialysis efficacy [5] Group 3: Product Information - Nafamostat is a synthetic serine protease inhibitor with anticoagulant, anti-inflammatory, and potential anti-viral activities, while Niyad is a lyophilized formulation of nafamostat currently under investigation as an anticoagulant for the extracorporeal circuit [6][8] - Niyad has received Breakthrough Device Designation Status from the FDA, indicating its potential significance in medical treatment [6]